Eli Lilly And Co Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ELI LILLY AND CO, and when can generic versions of ELI LILLY AND CO drugs launch?
ELI LILLY AND CO has six approved drugs.
There are seventeen US patents protecting ELI LILLY AND CO drugs.
There are two hundred and ninety-six patent family members on ELI LILLY AND CO drugs in fifty-four countries and thirty-seven supplementary protection certificates in eighteen countries.
Summary for Eli Lilly And Co
| International Patents: | 296 |
| US Patents: | 17 |
| Tradenames: | 7 |
| Ingredients: | 6 |
| NDAs: | 6 |
| Drug Master File Entries: | 37 |
| Patent Litigation for Eli Lilly And Co: | See patent lawsuits for Eli Lilly And Co |
| PTAB Cases with Eli Lilly And Co as petitioner: | See PTAB cases with Eli Lilly And Co as petitioner |
| PTAB Cases with Eli Lilly And Co as patent owner: | See PTAB cases with Eli Lilly And Co as patent owner |
Drugs and US Patents for Eli Lilly And Co
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eli Lilly And Co | OLUMIANT | baricitinib | TABLET;ORAL | 207924-001 | May 31, 2018 | RX | Yes | Yes | 8,158,616 | See Plans and Pricing | Y | Y | See Plans and Pricing | ||
| Eli Lilly And Co | VERZENIO | abemaciclib | TABLET;ORAL | 208716-004 | Sep 28, 2017 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | |||||
| Eli Lilly And Co | REYVOW | lasmiditan succinate | TABLET;ORAL | 211280-003 | Dec 18, 2020 | DISCN | Yes | No | 8,748,459 | See Plans and Pricing | See Plans and Pricing | ||||
| Eli Lilly And Co | OLUMIANT | baricitinib | TABLET;ORAL | 207924-001 | May 31, 2018 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | |||||
| Eli Lilly And Co | REYVOW | lasmiditan succinate | TABLET;ORAL | 211280-002 | Jan 31, 2020 | RX | Yes | Yes | 8,748,459 | See Plans and Pricing | See Plans and Pricing | ||||
| Eli Lilly And Co | OLUMIANT | baricitinib | TABLET;ORAL | 207924-002 | Oct 8, 2019 | RX | Yes | No | 8,158,616 | See Plans and Pricing | Y | Y | See Plans and Pricing | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Eli Lilly And Co
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Eli Lilly And Co | SARAFEM | fluoxetine hydrochloride | CAPSULE;ORAL | 018936-007 | Jul 6, 2000 | 4,971,998*PED | See Plans and Pricing |
| Eli Lilly And Co | PROZAC | fluoxetine hydrochloride | CAPSULE;ORAL | 018936-001 | Dec 29, 1987 | 4,035,511 | See Plans and Pricing |
| Eli Lilly And Co | PROZAC | fluoxetine hydrochloride | CAPSULE;ORAL | 018936-006 | Dec 23, 1992 | 4,314,081*PED | See Plans and Pricing |
| Eli Lilly And Co | PROZAC | fluoxetine hydrochloride | CAPSULE;ORAL | 018936-006 | Dec 23, 1992 | 4,018,895 | See Plans and Pricing |
| Eli Lilly And Co | AXIRON | testosterone | SOLUTION, METERED;TRANSDERMAL | 022504-001 | Nov 23, 2010 | 8,071,075 | See Plans and Pricing |
| Eli Lilly And Co | PROZAC | fluoxetine hydrochloride | CAPSULE;ORAL | 018936-001 | Dec 29, 1987 | 6,960,577 | See Plans and Pricing |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for ELI LILLY AND CO drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Topical Solution | 30 mg/1.5 mL | ➤ Subscribe | 2013-01-29 |
International Patents for Eli Lilly And Co Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Croatia | P20200222 | See Plans and Pricing |
| Hong Kong | 1136228 | See Plans and Pricing |
| Eurasian Patent Organization | 200900987 | See Plans and Pricing |
| Lithuania | 3258919 | See Plans and Pricing |
| Tunisia | 2010000415 | See Plans and Pricing |
| Hong Kong | 1073464 | See Plans and Pricing |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Eli Lilly And Co Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2379528 | 2019009 | Norway | See Plans and Pricing | PRODUCT NAME: ABEMACIKLIB ELLER FARMASOEYTISK AKSEPTABLE SALTER DERAV; REG. NO/DATE: EU/1/18/1307 20180927 |
| 2379528 | 9/2019 | Austria | See Plans and Pricing | PRODUCT NAME: ABEMACICLIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/18/1307 (MITTEILUNG) 20181001 |
| 2288610 | C02288610/01 | Switzerland | See Plans and Pricing | PRODUCT NAME: BARICITINIB; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66215 19.06.2017 |
| 2288610 | 132017000078559 | Italy | See Plans and Pricing | PRODUCT NAME: BARICITINIB E I SUOI SALI FARMACEUTICAMENTE ACCETTABILI(OLUMIANT); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/16/1170, 20170215 |
| 2379528 | CR 2019 00008 | Denmark | See Plans and Pricing | PRODUCT NAME: ABEMACICLIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/18/1307 20181001 |
| 2379528 | LUC00106 | Luxembourg | See Plans and Pricing | PRODUCT NAME: ABEMACICLIB ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES (VERZENIOS); AUTHORISATION NUMBER AND DATE: EU/1/18/1307 20181001 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
